BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Erbitux cetuximab: Completed Phase III enrollment

Merck KGaA disclosed in its 4Q10 earnings that it completed enrollment of 870 patients in the open-label, international Phase III EXPAND trial evaluating Erbitux in combination with cisplatin and Xeloda capecitabine. Erbitux is marketed to treat...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >